Some studies have reported the vasoconstriction of retinal arterioles due to a transient reduction of nitric oxide (NO) in the early stages following anti-VEGF therapy.[30,31] Theoretically, this transient vasoconstriction should result in a decrease in VD and FAZ enlargement, especially in DCP which is more vulnerable to ischemia.[30,32] Nevertheless, no evidence exists to indicate the endurance of this vasoconstriction, as demonstrated by the aforementioned studies. The gene discussed is VEGFA; the disease is ischemia.